| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Previous Article | Next Article ![]()
Mycobacterial Research Group, Centenary Institute of Cancer Medicine and Cell Biology, Locked Bag No. 6, Newtown, NSW 2042 Australia; Discipline of Medicine; Discipline of Infectious Diseases and Immunology, University of Sydney, NSW, 2006, Australia
* To whom correspondence should be addressed. Email:
jamiet{at}infdis.usyd.edu.au.
A strain of Mycobacterium bovis BCG that secretes high levels of functional murine Monocyte Chemotactic Protein-3 (BCGMCP-3) was developed. Mice vaccinated with BCGMCP-3 displayed increased lymphocyte migration in vivo and augmented antigen-specific T cell responses compared to BCG alone. The level of protection afforded by BCGMCP-3 was equivalent to control BCG, however immunodeficient mice infected with BCGMCP-3 survived significantly longer than mice infected with the control BCG strain. Therefore BCGMCP-3 may be a safer alternative than conventional BCG for vaccination of immunocompromised individuals.
Copyright (c) 2006, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
Secretion of functional Monocyte Chemotactic Protein-3 by recombinant Mycobacterium bovis BCG attenuates vaccine virulence and maintains protective efficacy against M. tuberculosis infection
![]()
Abstract
This article has been cited by other articles:
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|